This is MOPE’s second investment in the healthcare industry, the first one being in a medical equipment company
India Business Excellence Fund-IV, a fund managed and advised by MO Alternate Investment Advisors Private Limited (“MOPE”), has agreed to make a primary investment of upto Rs 194.4 crore (USD 25 million) in Pathkind Diagnostics.
Vishal Tulsyan, MD and CEO of MOPE said, “We believe that the diagnostics industry in India is poised to grow to $30 billion over the next 8-10 years, driven primarily by increasing penetration and shift towards organized diagnostics chains. Pathkind, with its focus on providing quality testing, widespread network, extensive doctor coverage, strong management team and parentage and with our investment, is well poised to be a leading diagnostics franchise in India.”
This is MOPE’s second investment in the healthcare industry, the first one being in a medical equipment company.
Sanjeev Vashishta, MD and CEO of Pathkind said, “Settin up labs run by qualified pathologist doctors, skilled technicians and scientists in every nook and corner of the country using state of the art technology and automated platforms, such that the patients don’t have to travel long distances for their diagnostics requirements, is our top priority. The funding will be utilised judiciously to further build on the diagnostics capabilities and capacities, educating the masses about the virtues of early diagnosis and to augment ourservices using digitization, AI, ML tools apart apart from other things.”
Khaitan & Co, Wadia Ghandy & Co, and Ray Legal were the legal advisors to the transaction.